WB result of N-Myc Recombinant Rabbit mAb
Primary antibody: N-Myc Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: HeLa whole cell lysate 20 µg
Lane 2: K562 whole cell lysate 20 µg
Lane 3: IMR-32 whole cell lysate 20 µg
Negative control: HeLa whole cell lysate; K562 whole cell lysate
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 50 kDa
Observed MW: 56 kDa
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | N-Myc |
| Synonyms | N-myc proto-oncogene protein; Class E basic helix-loop-helix protein 37 (bHLHe37); BHLHE37; NMYC; MYCN |
| Immunogen | Synthetic Peptide |
| Location | Nucleus |
| Accession | P04198 |
| Clone Number | S-2729-50 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB, ICC |
| Reactivity | Hu |
| Positive Sample | IMR-32 |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000-1:2000 | Hu |
| ICC | 1:500 | Hu |
Background
N-Myc is a 64-kDa basic-helix–loop–helix–leucine-zipper transcription factor encoded by MYCN on 2p24 whose amplification or enhancer hijacking defines high-risk subsets of neuroblastoma, medulloblastoma and rhabdomyosarcoma; it heterodimerizes with MAX to bind the E-box CACGTG, recruits TRRAP–TIP60 and p300/CBP to unleash transcription of ribosomal proteins, nucleotide and polyamine biosynthetic enzymes, as well as miR-17-92, thereby driving rapid G1-S transit, metabolic rewiring toward glutaminolysis and serine synthesis, and suppression of differentiation; its intrinsically disordered N-terminus is stabilized by Aurora-A–mediated cis-prolyl isomerization that blocks ubiquitination by FBXW7, while phosphorylation at Ser62 by CDK1 primes subsequent phosphorylation at Thr58 by GSK3β to trigger SCFβ-TrCP-mediated degradation, and BET-bromodomain or HDAC inhibitors can restore this degradation in tumors harboring MYCN amplification, making N-Myc a validated but still elusive therapeutic target.
Picture
Picture
Western Blot
Immunocytochemistry
ICC shows positive staining in IMR-32 cells (top panel) and negative staining in HeLa cells (below panel). Anti- N-Myc antibody was used at 1/500 dilution (Green) and incubated overnight at 4°C. Goat polyclonal Antibody to Rabbit IgG - H&L (Alexa Fluor® 488) was used as secondary antibody at 1/1000 dilution. The cells were fixed with 4% PFA and permeabilized with 0.1% PBS-Triton X-100. Nuclei were counterstained with DAPI (Blue). Counterstain with tubulin (Red).
